 SAN DIEGO, April 05, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 12 SWORD-1 study of its RET inhibitor drug candidate, TPX-0046. 